Ignite Creation Date:
2024-05-19 @ 5:34 PM
Last Modification Date:
2024-10-26 @ 3:30 PM
Study NCT ID:
NCT06419582
Status:
RECRUITING
Last Update Posted:
2024-07-11
First Post:
2024-05-14
Brief Title:
BHV-7000 Acute Treatment of Bipolar Mania
Sponsor:
Biohaven Therapeutics Ltd
Organization:
Biohaven Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 23 Multicenter Inpatient Placebo-Controlled Double-blind Trial of BHV-7000 for the Acute Treatment of Manic Episodes With or Without Mixed Features Associated With Bipolar I Disorder
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether BHV-7000 is a safe and effective acute treatment for manic episodes in bipolar disorder I
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None